ProPhase Labs, Inc. Increase Decrease In Operating Lease Liability
ProPhase Labs, Inc. (PRPH) reported Increase Decrease In Operating Lease Liability of $71.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-19
- ProPhase Labs, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was $32.00K.
- ProPhase Labs, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was $39.00K, a 333.33% increase year-over-year.
- ProPhase Labs, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$82.00K.
- ProPhase Labs, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$122.00K.
- ProPhase Labs, Inc. increase decrease in operating lease liability for fiscal 2025 was -$233.00K.
- ProPhase Labs, Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.41M.
- ProPhase Labs, Inc. increase decrease in operating lease liability for fiscal 2023 was -$181.00K.
- ProPhase Labs, Inc. increase decrease in operating lease liability for fiscal 2022 was -$301.00K, a 331.54% decline from fiscal 2021.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 6 month as first filed | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 9 month as first filed | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $32.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $71.00K 10-Q · filed 2026-08-19 | -$11.00K derived: sum of 3 quarters · filed 2026-08-19 | -$133.00K derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2026-03-31 | $39.00K 10-Q/A · filed 2026-07-09 | -$43.00K derived: sum of 2 quarters · filed 2026-07-09 | -$165.00K derived: sum of 3 quarters · filed 2026-07-09 | -$203.00K derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-12-31 | -$82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$204.00K derived: sum of 2 quarters · filed 2026-06-01 | -$242.00K derived: sum of 3 quarters · filed 2026-08-19 | -$233.00K 10-K · filed 2026-06-01 | ||
| 2025-09-30 | -$122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$160.00K derived: sum of 2 quarters · filed 2026-08-19 | -$151.00K 10-Q · filed 2025-11-19 | -$155.00K derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-06-30 | -$38.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | -$29.00K 10-Q · filed 2026-08-19 | -$33.00K derived: sum of 3 quarters · filed 2026-08-19 | -$510.00K derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-03-31 | $9.00K 10-Q/A · filed 2026-07-09 | $5.00K derived: sum of 2 quarters · filed 2026-07-09 | -$472.00K derived: sum of 3 quarters · filed 2026-07-09 | -$940.00K derived: sum of 4 quarters · filed 2026-07-09 | ||
| 2024-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$481.00K derived: sum of 2 quarters · filed 2026-06-01 | -$949.00K derived: sum of 3 quarters · filed 2026-06-01 | -$1.41M 10-K · filed 2026-06-01 | ||
| 2024-09-30 | -$477.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$945.00K derived: sum of 2 quarters · filed 2025-11-19 | -$1.40M 10-Q · filed 2025-11-19 | -$1.71M 10-Q · filed 2024-11-13 | -$1.45M derived: sum of 4 quarters · filed 2025-11-19 | |
| 2024-06-30 | -$468.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$927.00K 10-Q · filed 2025-08-13 | -$895.00K 10-Q · filed 2024-08-14 | -$969.00K derived: sum of 3 quarters · filed 2025-08-13 | -$954.00K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$459.00K 10-Q · filed 2025-05-20 | -$501.00K derived: sum of 2 quarters · filed 2025-05-20 | -$486.00K derived: sum of 3 quarters · filed 2025-05-20 | -$560.00K derived: sum of 4 quarters · filed 2025-05-20 | ||
| 2023-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | -$27.00K derived: sum of 2 quarters · filed 2025-04-01 | -$101.00K derived: sum of 3 quarters · filed 2025-04-01 | -$181.00K 10-K · filed 2025-04-01 | ||
| 2023-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$59.00K derived: sum of 2 quarters · filed 2024-11-13 | -$139.00K 10-Q · filed 2024-11-13 | -$217.00K derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | -$74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$154.00K 10-Q · filed 2024-08-14 | -$232.00K derived: sum of 3 quarters · filed 2024-08-14 | -$308.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$80.00K 10-Q · filed 2024-05-10 | -$158.00K derived: sum of 2 quarters · filed 2024-05-10 | -$234.00K derived: sum of 3 quarters · filed 2024-05-10 | -$308.00K derived: sum of 4 quarters · filed 2024-05-10 | ||
| 2022-12-31 | -$78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$154.00K derived: sum of 2 quarters · filed 2024-03-29 | -$228.00K derived: sum of 3 quarters · filed 2024-03-29 | -$301.00K 10-K · filed 2024-03-29 | ||
| 2022-09-30 | -$76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$150.00K derived: sum of 2 quarters · filed 2023-11-13 | -$223.00K 10-Q · filed 2023-11-13 | -$290.00K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | -$74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$147.00K 10-Q · filed 2023-08-11 | -$214.00K derived: sum of 3 quarters · filed 2023-08-11 | -$222.00K derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | -$73.00K 10-Q · filed 2023-05-12 | -$140.00K derived: sum of 2 quarters · filed 2023-05-12 | -$148.00K derived: sum of 3 quarters · filed 2023-05-12 | |||
| 2021-12-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$75.00K derived: sum of 2 quarters · filed 2023-03-29 | $130.00K 10-K · filed 2023-03-29 | |||
| 2021-09-30 | -$8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $197.00K 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $205.00K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |